Substitute for form 1449A/PTO		CO CE IF KNOWN
INFORMATION DISCLOSURE	Application Number	10/517,295
STATEMENT BY APPLICANT	Filing Date	December 7, 2004
STA LEMENT BY APPLICANT	First Named Inventor	Steven S. Carroll, et al.
MAR 0 9 2005 E (use a phany sheets as necessary)	Group Art Unit	1623
	Examiner Name	
Sheet PARKET I of 3	Attorney Docket Number	21122YP

			U.S. PA	TENT DOCUMENTS		
Examiner Initials*			Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
WO	1	6,777,395	B2	Bhat et al.	08/17/2004	
5	2	6,812,219	bl	LaColla et al.	11/02/2004	
	3	US 2003/0060400	A2	LaColla et al.	03/27/2003	
	4	US 2003/0050229	AI	Sommadossi et al.	03/13/2003	
>	5	US 2004/0097461	A	Sommadossi et al.	05/20/2004	
ζ	6	US 2004/0072788	81	Bhat et al.	04/15/2004	
	7	US 2004/0147464	181	Roberts et al.	07/29/2004	
Re	.8	US 2004/0063658	A	Roberts et al.	04/01/2004	
T						
T_{-}						

				FOREI	GN PATENT	T DOCUMENTS	
	miner ials*	Cite No.	Foreign Patent Document Office Number		t Kind Code (if known)	Name of Patentee or Applic of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
(A	160	9	PCT	WO02/057425	Ar	Merck & Co., Inc.	07/25/2002
	\	10	PCT	WO02/32920	B2	Pharmasset Limited	04/25/2002
)	11	PCT	WO03/093290	RJ.	Genelabs Technologies, Inc.	11/13/2003
		12	PCT	WO02/057287	42	Merck & Co., Inc.	07/25/2002
)	13	PCT	WO01/92282	AZ	Novirio Pharmaceuticals Limi	ited 12/06/2001
L		14	PCT	WO01/90121	AZ	Novirio Pharmaceuticals Limi	ited 11/29/2001
		15	PCT	WO03/051899	Al	Ribapharm Inc.	06/26/2003
L		16	PCT	WO03/062255	AZ	Ribapharm Inc.	07/31/2003
L	. 7	17	PCT	WO03/062256	AI	Ribapharm Inc.	07/31/2003
	60	18	PCT	WO2004/065398	A2	Ribapharm Inc.	08/05/2004
ES	xamin gnatu	er ire	L.	E. Crane	M. lea	Date Considered	09/24/2006

*Examiner: Initial if reference considered, whether or not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449APTO		E IF KNOWN
INFORMATION DISCLOSURE	Application Number	10/517,295
6 STATEMENT BY APPLICANT	Filing Date	December 7, 2004
%'	First Named Inventor	Steven S. Carroll et al.
MAR 0 9 2005 E	Group Art Unit	1623
(use at many sheets as necessary)	Examiner Name	
Sheet PARELLY 2 of 3	Attorney Docket Number	21122YP

	U.S. PATENT DOCUMENTS					
Examiner nitials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
			-			
			-			
1			-	· · · · · · · · · · · · · · · · · · ·		
\vdash						

			FC	REIGN PA	TEN	DOCUMENTS		
Examiner Initials*	Cite No.	Office	Foreign Patent Do	ŀ	Kind Code known)	Name of Patentee or Applica of Cited Document	nt	Date of Publication of Cited Document MM-DD-YYYY
Kel	19	PCT	WO2004/028481		A2	Genelabs Technologies, Inc.		04/08/2004
	20	PCT	WO2004/002999		AZ	Idenix (Cayman) Limited		01/08/2004
	21	PCT	WO2004/002422		12	Idenix (Cayman) Limited		01/08/2004
We	22	PCT	WO2004/046331		BI	Idenix (Cayman) Limited		06/03/2004
Examin Signatu		I	. E. Crane	11/5	Cer	Date Considered	09	/24/2006

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		-(ie if known
•	Substitute for form 1449B/PTO INFORMATION	DIS	CLOSURE	Application Number	10/5 17,295
	STATINGENT BY			Filing Date	December 7, 2004
1 0	ο 1	Aľ	PLICANI	First Named Inventor	Steven S. Carroll, et al.
MA	R 0 9 2005 E			Group Art Unit	1623
20	(use a many sheets	as r	necessary)	Examiner Name	
She		of	3	Attorney Docket Number	21122YP

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
Me	23	Anne B. Eldrup et al., "Structure-Activity Relationship of Heterobase-Modified 2'-C-Methyl Ribonucleosides as Inhibitors of Hepatitis C Virus RNA Replication", J. Med. Chem., Vol. 47, pp. 5284-5297 (2004)
	24	Anne B. Eldrup et al., "Structure-Activity Relationship of Purine Ribonucleosides for Inhibition of Hepatitis C Virus RNA-Dependent RNA Polymerase", J. Med. Chem., Vol. 47, pp. 2283-2295 (2004)
	25	David B. Olsen et al., "A 7-Deaza-Adenosine Analog is a Potent and Selective Inhibitor of Hepatitis C Virus Replication with Excellent Pharmacokinetic Properties", Antimicrobial Agents and Chemotherapy, Vol. 48, No. 10, pp. 3944-3953 (2004)
	26	Per Hoffmann et. al., "Recent Patents on Experimental Therapy for Hepatitis C Virus Infection", Expert Opin. Ther. Patents, Vol. 13(11), pp. 1707-1723, (2003)
Re	27	Volker Brass et al., "Recent Developments in Target Identification against Hepatitis C Virus", Expert Opin. Ther. Targets, Vol. 8(4), pp. 295-307, (2004)

Examiner Signature L. E. Crane Mile Canal Date Considered 09/24/2006

*Examiner: Initial if reference considered, whether proof citation is in cw ormance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.